What is ceftriaxone and sulbactam injection used for?
Pharmaceutical Product Monograph: Ceftriaxone-Sulbactam Sodium (1.5 g)
In the pharmaceutical industry, Ceftriaxone-Sulbactam is a parenteral, fixed-dose combination (FDC) of a Third-Generation Cephalosporin and a Beta-lactamase Inhibitor. As a pharmacist and manufacturer, I view this molecule as an “Empirical Powerhouse”—it is technically designed to restore the efficacy of Ceftriaxone against bacteria that have evolved to produce destructive enzymes (beta-lactamases).
At your WHO-GMP facility in Mumbai, the 1.5 g strength (typically 1 g Ceftriaxone + 500 mg Sulbactam) is a flagship SKU for Critical Care and Institutional portfolios. It is the “Step-Up” therapy used when standard Ceftriaxone monotherapy is likely to fail due to suspected antibiotic resistance.
Therapeutic Profile: Primary Indications
Ceftriaxone-Sulbactam is indicated for severe infections where “Extended Spectrum Beta-Lactamase” (ESBL) producing organisms are suspected.
| Indication | Clinical Context | Technical Rationale |
| Intra-abdominal Infections | Peritonitis / Abscesses | Effective against resistant E. coli and Klebsiella species commonly found in the gut. |
| Severe RTI | HAP / VAP | Used for hospital-acquired pneumonia where pathogens are more likely to be resistant. |
| Gynaecological Infections | PID / Endometritis | Provides broader coverage for pelvic inflammatory diseases involving mixed aerobic/anaerobic flora. |
| Surgical Prophylaxis | High-Risk Surgery | Used in “dirty” surgeries where the risk of resistant post-operative sepsis is high. |
| Complicated UTI | Pyelonephritis | The treatment of choice for resistant urinary tract infections that have failed first-line therapy. |
Mechanism: The “Shield and Sword” Strategy
The combination works through a synergistic biochemical mechanism to overcome bacterial defenses:
Ceftriaxone (The Sword): It binds to Penicillin-Binding Proteins (PBPs), inhibiting the cross-linking of the bacterial cell wall, leading to osmotic instability and bacterial lysis.
Sulbactam (The Shield): Many resistant bacteria produce Beta-lactamase enzymes that “eat” the Ceftriaxone molecule. Sulbactam is a “suicide inhibitor” that binds permanently to these enzymes, “sacrificing” itself so that Ceftriaxone can reach its target PBP unharmed.
Synergy: Technically, Sulbactam expands the spectrum of Ceftriaxone to include many strains of Acinetobacter, Bacteroides, and Staphylococci that would otherwise be resistant.
The Pharmacist’s “Technical Warning”
The “Calcium” Contraindication: As a pharmacist, I must reiterate the Critical Safety Warning: This combination must never be mixed or given with calcium-containing IV fluids (like Ringer’s Lactate), as it forms fatal precipitates in the lungs and kidneys.
Sequential Therapy: While the injection is highly potent, once the patient is stable, clinicians often switch to an oral Beta-lactam/Inhibitor combination to complete the course.
Renal & Hepatic Dosing: Because Ceftriaxone has dual excretion, dose adjustment is technically not needed unless both renal and hepatic functions are severely impaired.
The “Lidocaine” IM Rule: For Intramuscular (IM) use, the 1.5 g dose must be reconstituted with 1% Lidocaine to manage the intense pain of the injection. This is for IM use only.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Homogenous Blend” USP: On your digital marketplace, highlight your Vacuum-Assisted Co-Filling. Ceftriaxone Sodium and Sulbactam Sodium have different bulk densities; ensuring a perfectly uniform 2:1 ratio in every vial is a technical hallmark of WHO-GMP quality.
The “ESBL-Market” Advantage: For international B2B tenders (especially in South Asia and Africa), market this combination as the cost-effective alternative to Carbapenems (like Meropenem). It is a key tool for Antibiotic Stewardship.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ceftriaxone-Sulbactam 1.5 g to support your registration in international B2B tenders for critical care and surgery.